Nutrien Ltd. (NTR) Stock Forecast
Data as of May 2, 2026Basic Materials · Current price $75.34 (-0.87%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 13, 2026 | Michael Sison | Wells Fargo | $100.00 | +32.7% |
| Jan 20, 2026 | Andrew Wong | RBC Capital | $75.00 | -0.5% |
| Sep 4, 2025 | Michael Doumet | National Bank | $64.00 | -15.1% |
| Jul 11, 2025 | Paul Cheng | Scotiabank | $133.00 | +76.5% |
| Jul 11, 2025 | Joseph Stauff | Susquehanna | $86.00 | +14.1% |
| Jul 11, 2025 | Susan Anderson | Canaccord Genuity | $26.00 | -65.5% |
| Jul 11, 2025 | Laurence Alexander | Jefferies | $66.00 | -12.4% |
| Jun 17, 2025 | Steve Hansen | Raymond James | $68.00 | -9.7% |
| Nov 18, 2024 | Charles Neivert | Piper Sandler | $50.00 | -33.6% |
| Sep 24, 2024 | Richard Garchitorena | Wells Fargo | $50.00 | -33.6% |
| Sep 10, 2024 | Adam Samuelson | Goldman Sachs | $53.00 | -29.7% |
| Aug 9, 2024 | Jacob Bout | CIBC | $64.00 | -15.1% |
| Aug 9, 2024 | Joel Jackson | BMO Capital | $75.00 | -0.5% |
| Aug 8, 2024 | Edlain Rodriguez | Mizuho Securities | $52.00 | -31.0% |
| Jul 15, 2024 | Andrew Wong | RBC Capital | $60.00 | -20.4% |
| Jun 13, 2024 | Joel Jackson | BMO Capital | $80.00 | +6.2% |
| Jun 12, 2024 | John Roberts | UBS | $67.00 | -11.1% |
| May 17, 2024 | Charles Neivert | Piper Sandler | $56.00 | -25.7% |
| May 13, 2024 | Vincent Anderson | Stifel Nicolaus | $69.00 | -8.4% |
| May 13, 2024 | Ben Isaacson | Scotiabank | $66.00 | -12.4% |
Top Analysts Covering NTR
NTR vs Sector & Market
| Metric | NTR | Basic Materials Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.64 | 2.36 | 2.41 |
| Analyst Count | 28 | 7 | 18 |
| Target Upside | +11.8% | +54.0% | +14.9% |
| P/E Ratio | 16.16 | -16.66 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $25.46B | $27.46B | $34.79B | 11 |
| 2027-03-31 | $5.31B | $5.45B | $5.66B | 2 |
| 2027-06-30 | $10.31B | $10.57B | $10.99B | 2 |
| 2027-09-30 | $5.47B | $5.61B | $5.83B | 2 |
| 2027-12-31 | $5.18B | $5.31B | $5.52B | 2 |
| 2028-03-31 | $5.38B | $5.51B | $5.73B | 1 |
| 2028-06-30 | $9.83B | $10.08B | $10.48B | 1 |
| 2028-09-30 | $4.87B | $5.00B | $5.20B | 1 |
| 2028-12-31 | $4.60B | $4.72B | $4.91B | 1 |
| 2029-12-31 | $25.99B | $27.73B | $31.40B | 7 |
| 2030-12-31 | $26.64B | $28.42B | $32.18B | 7 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $4.74 | $5.42 | $6.53 | 11 |
| 2027-03-31 | $0.67 | $0.69 | $0.73 | 4 |
| 2027-06-30 | $2.77 | $2.87 | $3.01 | 4 |
| 2027-09-30 | $0.92 | $0.95 | $1.00 | 4 |
| 2027-12-31 | $0.97 | $1.00 | $1.05 | 4 |
| 2028-03-31 | $0.61 | $0.63 | $0.66 | 5 |
| 2028-06-30 | $2.41 | $2.49 | $2.62 | 5 |
| 2028-09-30 | $0.36 | $0.37 | $0.39 | 5 |
| 2028-12-31 | $0.43 | $0.44 | $0.46 | 5 |
| 2029-12-31 | $4.31 | $4.69 | $5.50 | 1 |
| 2030-12-31 | $4.86 | $5.29 | $6.20 | 1 |
Frequently Asked Questions
What is the analyst consensus for NTR?
The consensus among 28 analysts covering Nutrien Ltd. (NTR) is Hold with an average price target of $84.00.
What is the highest price target for NTR?
The highest price target for NTR is $133.00, set by Paul Cheng at Scotiabank on 2025-07-11.
What is the lowest price target for NTR?
The lowest price target for NTR is $26.00, set by Susan Anderson at Canaccord Genuity on 2025-07-11.
How many analysts cover NTR?
28 analysts have issued ratings for Nutrien Ltd. in the past 12 months.
Is NTR a buy or sell right now?
Based on 28 analyst ratings, NTR has a consensus rating of Hold (2.64/5) with a +11.8% upside to the consensus target of $84.00.
What are the earnings estimates for NTR?
Analysts estimate NTR will report EPS of $5.42 for the period ending 2026-12-31, with revenue estimated at $27.46B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.